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ABSTRACT

According to the World Health Organization (WHO), hypertension is a major risk
factor for cardiovascular disease (CVD), renal impairment, peripheral vascular disease,
and blindness. In Panama, a recent study estimated the prevalence of hypertension at
38.5% in the two main provinces of the country, with a rate of uncontrolled hypertension
of 47.2%. The aims of this study were to assess the feasibility of the study design and to
describe the characteristics of the hypertensive population and the physician’s adherence
to Panamanian antihypertensive protocols and their relationship with uncontrolled
hypertension.
This is a cross-sectional study of adult hypertensive patients attending a primary
healthcare facility in Panama City. Clinical charts from eligible participants were
examined to describe the demographic and clinical characteristics related to uncontrolled
hypertension and the use of antihypertensive protocols by medical doctors. Descriptive
and central tendency statistics were used to characterize the study population. Bivariate
relationships between demographic and clinical characteristics, and uncontrolled
hypertension were explored using specific test for no association. Logistic regression
modeling was used to examine the association between physician’s adherence to
antihypertensive protocols and the presence of uncontrolled hypertension.
In this study the mean age was 56.7 years (±13.6); 58.1% of participants were
females; 71.3% of participants had body mass index >25.0kg/m2; and 53.0% of
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participants had stage 2 hypertension. Uncontrolled hypertension was present in 66.7% of
the study sample. 82.9% of participants had one or more comorbidities. The medical
doctors were compliant with antihypertensive protocols in 43.6% of participants,
primarily due to lower compliance with lifestyle modification recommendations. In the
multivariate analysis, a significant interaction was found with age, suggesting that age is
a potential effect modifier.
The rate of uncontrolled hypertension was high among this study population.
Nearly half of the attending physicians did not follow the recommendations given by
current antihypertensive protocols. Further research is necessary to explore the
relationships between subject characteristics, such as age, number of comorbidities, and
the presence of diabetes mellitus with uncontrolled hypertension.
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CHAPTER ONE: UNCONTROLLED HYPERTENSION AND ASSOCIATED
RISK FACTORS

Hypertension Epidemiology
Hypertension (High Blood Pressure, HBP) is defined as a systolic blood pressure
≥140 mmHg and/or a diastolic blood pressure ≥90 mm Hg, the use of antihypertensive
medication, or being told at least twice by a physician or other health professional that
one has HBP (Roger et al., 2012).
According to the World Health Organization (WHO), hypertension is a major risk
factor for cardiovascular disease (CVD, excluding congenital CVD) as well as renal
impairment, peripheral vascular disease, and blindness. Hypertension is estimated to
cause 7.5 million deaths worldwide annually, about 12.8% of the total deaths (Mendis,
Puska, & Norrving, 2011). In the same report, WHO estimates the prevalence of
hypertension in high-income countries as 35% for both genders, while in low, lowermiddle and upper-middle income countries the prevalence is around 40%. Hypertension
prevalence estimates from a study in seven Latin-American cities range from 13% to
29%, with an overall prevalence of 18% (Schargrodsky et al., 2008). However, in a
recent study developed by the WHO in six middle-income countries around the world
(including a Latin American country), the prevalence of hypertension was 37% (Basu &
Millett, 2013).
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In Panama, a study estimated the prevalence of hypertension at 38.5% in the two
main provinces of the country (McDonald et al., 2012). In 2009, according to the
Ministry of Health of Panama, primary hypertension (under the codes of the Tenth
Edition of the International Classification of Diseases; World Health Organization
[WHO], 2010) was the fourth reason for seeking care in those aged 20-59; while for those
aged 60 and older, it was the leading cause (Ministerio de Salud, 2010).

Hypertension Classification and Control
There are two main hypertension classifications: the European Society of
Hypertension/European Society of Cardiology (ESH/ESC) classification (Mancia et al.,
2007), and the Seventh Report of the Joint National Committee on Prevention,
Detection, Evaluation, and Treatment of High Blood Pressure of the National Heart,
Lung, and Blood Institute (JNC 7 Report) classification (Chobanian et al., 2003).
Both are based on at least two blood pressure measurements using a sphygmomanometer,
recording as systolic blood pressure phase I Korotkoff sounds, and as diastolic blood
pressure phase V Korotkoff sounds (Chobanian et al., 2003; Mancia et al., 2007). Both
classifications use >140/90 mmHg as the cut point to diagnose hypertension.
According to the WHO, approximately one billion persons are living with
uncontrolled hypertension worldwide (Mendis, Puska, & Norrving, 2011). In the United
States, the prevalence of uncontrolled hypertension is estimated to be 53.5% of those
with hypertension, affecting approximately 35.8 million persons (Centers for Disease
Control and Prevention [CDC], 2012a). In a recent study in middle income countries it
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was found that approximately 33.3% of hypertensive patients were uncontrolled (Basu &
Millett, 2013). In Panama among hypertensive patients who receive medication, the rate
of uncontrolled hypertension was 47.2% (McDonald et al., 2012).

Benefits in Controlling Hypertension
Several studies had shown the relationship between blood pressure and the risk of
a cardiovascular event. As was stated by Chobanian et al. (2003), for each increase of 20
mmHg in systolic blood pressure and 10 mmHg in diastolic blood pressure the risk of
ischemic heart disease and stroke is doubled. In the same report it was also established
that the relationship between blood pressure and risk of cardiovascular disease (heart
attack, heart failure, stroke, and kidney diseases) is continuous, consistent and
independent of other risk factors, such as high cholesterol, low levels of high-density
lipoprotein, smoking, diabetes and left ventricular hypertrophy.
The benefits of blood pressure level reduction were demonstrated in the VALUE
study (Weber et al., 2004), in which a lower incidence of cardiovascular disease and
mortality was observed in those with controlled hypertension compared to those with
uncontrolled hypertension (blood pressure >140/90mmHg). In addition, in the FEVER
study (Liu et al., 2005) a 28% reduction in coronary disease, stroke and cardiovascular
mortality was demonstrated in those randomized to active antihypertensive treatment,
compared to those randomized to placebo.
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Improving Hypertension Control
Hypertension control is a complex issue which, to be achieve, needs active
cooperation between physicians, patients, healthcare personnel and healthcare systems
(Chobanian et al., 2003; Mancia et al., 2007). The fist step to address the uncontrolled
hypertension problem is to develop local comprehensive hypertension prevention and
treatment guidelines based in well-designed studies. However, these guidelines need to
be accepted by all medical societies to facilitate their implementation. Medical doctors
need to be informed about guidelines recommendations but also is necessary an audit
process that could assess the implementation phase appropriately (Mancia et al., 2007).
Patient treatment compliance is a complicated problem that is influenced by factors such
as cultural behaviors and beliefs, and previous experiences in the healthcare systems
(Chobanian et al., 2003). The healthcare system plays a central role in the hypertension
control, and is the responsible to provide the necessary tools and audit to guarantee the
correct guidelines implementation (Mancia et al., 2007).
The Panamanian national health authorities (Ministry of Health and the Social
Security Fund), to tackle the hypertension problem developed a structured program to
address hypertension in cooperation with the Pan American Health Organization in 2009
(Organización Panamericana de la Salud, 2009). This is a comprehensive program which
encompass several aspects in hypertension prevention and treatment, however there are
scarce published data regarding the status of patients treated in primary healthcare
settings in Panama.
This study aims to provide information about the feasibility to conduct a larger
study, and to describe and analyze selected aspects of the hypertensive population.
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CHAPTER TWO: RESEARCH OBJECTIVES

Objectives
This study was designed as a feasibility study to assess the current treatment
practices and to describe select demographic and clinical characteristics of hypertensive
adults attending the primary healthcare center Luis H. Moreno in Panama City, Republic
of Panama.
The main research question was whether physician adherence to antihypertensive
protocol recommendations would be associated with patient’s blood pressure control
status.
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CHAPTER THREE: METHODOLOGY

Study Design
This is a cross-sectional study of adult hypertensive patients who attended a
primary healthcare facility in Panama City, Republic of Panama and received treatment
for hypertension during the year 2012. Clinical charts from eligible participants were
examined to describe the demographic and clinical characteristics related to uncontrolled
hypertension and physician’s adherence to antihypertensive protocols. Descriptive and
central tendency statistics were used to characterize the study population. Bivariate
relationships between demographic and clinical characteristics, and uncontrolled
hypertension were explored using the chi-square or the Fisher’s exact test for categorical
distributions, the t-test for parametric continuous distributions, and the Wilcoxon sumrank test for non-parametric continuous distributions. Finally, logistic regression
modeling was used to examine the association between the physician’s adherence to
antihypertensive protocols and uncontrolled hypertension after adjusting for other factors.
Prior to data collection, approvals from the University of South Florida’s Institutional
Review Board (IRB) and from the authorized Panamanian IRB (Punta Pacifica Hospital’s
IRB) were obtained.
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Eligibility Criteria
Eligible subjects were all adult patients (>18 years old), who were treated in
the center between January 1st, 2012 and December 31, 2012 and had a diagnosis of
primary hypertension (WHO, 2010). Patients with a diagnosis of primary
hypertension made during the year 2009 or later, and those initially diagnosed before
2009 who had not taken hypertensive medication for at least 6 months and re-entered
treatment in 2009 or later; were included in the study.
Criteria for exclusion included clinical charts with missing information on the
appointment at which the antihypertensive pharmacological treatment was initiated, and
those for which inadequate information was available to establish whether appropriate
treatment was received and whether blood pressure control was obtained. Additional
exclusion criteria included patients who had kept regular hypertension control
appointments for less than six months, and pregnant women (since the treatment and
classification of hypertensive pregnancy disease is different from primary hypertension)
(Mancia et al., 2007).

Study Sample and Sample Selection
The needed sample size to develop the study was obtained using the formula
developed by Cochran (1963) for proportions in large populations:
n = [Z^2 P(1-P)]/d^2 → n ≈ 383 participants
Where: n = sample size; Z = Z statistics for the level of confidence of 95%
(1.96 for two tailed test); P = Prevalence of uncontrolled
hypertension in Panama (0.472); d = Precision (0.05).
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For the sample size calculation, the prevalence of uncontrolled hypertension was
obtained from a previous study (McDonald et al., 2012) that found that 47.2% of
hypertensive patients receiving treatment did not achieve blood pressure goals.
A simple random sample of 383 clinical charts were selected for review, from
the existing electronic log of all patients who attended the study center between January
1, 2012 and December 31, 2012 with a diagnosis of primary hypertension (WHO, 2010).
Demographic data collected included age and gender. Race/ethnicity was not
available in the charts and could not be collected. The clinical data that were
collected included: date at which the pharmacological treatment was initiated
(hereafter “treatment appointment”), date of follow-up (hereafter “follow-up
appointment”), height (meters) and weight (kilograms) at the first appointment,
blood pressure from the first and second appointments, presence of comorbidities,
prescribed antihypertensive medication, type of attending physician (general
practitioner and specialist), and if any recommendation of lifestyle modification was
made during the treatment appointment (Appendix A). The clinical chart of each
patient was reviewed, and those that met the additional eligibility criteria (diagnosis in
2009 or later, and those with a diagnosis prior to 2009 with at least 6 months of no
antihypertensive therapy who had re-entered treatment in 2009 or later) were included in
the study. Of the 383 clinical charts that were examined, only 117 clinical charts met the
eligibility criteria for inclusion in the study.
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Operational Definition of Variables
Demographic Variables. Age: the age of the patient at the treatment
appointment, calculated based on the date of birth and date of the treatment
appointment.
Gender: Female or male, as recorded in the clinical chart.

Clinical Variables. Treatment Appointment: the appointment at which the
antihypertensive pharmacological treatment was initiated, or was re-initiated for
those previously receiving treatment.
Follow-up Appointment: the appointment recorded as the hypertension
follow-up appointment or the appointment in which the first antihypertensive
medication refill was made, whichever occurred first.
Height and Weight: the height (meters) and weight (kilograms) to calculate
the body mass index (BMI) category [CDC], 2012b).
Blood Pressure: systolic and diastolic blood pressure as recorded by the
attending physician at both the treatment and follow-up appointments.
Presence of Comorbidities: the comorbidities noted in the chart at the
treatment appointment that are listed in the Pan American Health Organization
Guidelines (PAHO; Organización Panamericana de la Salud, 2009) as comorbidities
to be considered in the protocol for hypertension treatment (Appendix B).
Lifestyle Modifications: recorded as “Yes” if there were any notes in the
clinical chart regarding recommendations following the PAHO Guidelines for
lifestyle modifications during the treatment appointment.
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Antihypertensive Medication: all antihypertensive medications prescribed at
the treatment appointment.
Type of Physician: the specialty of the attending physician: general
practitioner or specialist.

Assessment of Treatment Compliance with Antihypertensive Protocols
	
  

In 2009, the Pan American Health Organization (PAHO), in cooperation with

the Panamanian health authorities (Ministry of Health and the Social Security Fund),
issued the Comprehensive Guidelines for the Hypertensive Population Treatment
(PAHO Guidelines; Organización Panamericana de la Salud, 2009). This report
established the procedures for prevention, detection, diagnosis and treatment of high
blood pressure within the country. These guidelines were used to assess adherence to
treatment protocols by attending physician.
The guidelines state that the antihypertensive treatment should consist of both
lifestyle modifications and pharmacological treatment. These two variables were
used together to establish physician’s adherence to antihypertensive protocols, as
described in the two following sections.
Assessment of lifestyle modification recommendations. The lifestyle
modification variable was recorded as “Yes” if there was a note recommending any of the
suggested lifestyle modifications listed in the PAHO Guidelines for the nonpharmacological treatment of hypertension. The lifestyle modifications considered were:
physical activity, stress reduction, tobacco cessation, limiting of alcohol use, weight
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control, reducing sources of sodium, cholesterol and triglycerides in the diet, and
adequate rest (six to eight hours daily).
Assessment of pharmacological treatment adherence with antihypertensive
protocols. From clinical data abstracted in the treatment appointment, patients were
classified based on the categories of the Seventh Report of the Joint National
Committee on Prevention, Detection, Evaluation, and Treatment of High Blood
Pressure (JNC 7 Report) of the National Heart, Lung, and Blood Institute (Chobanian
et al., 2003).
The pharmacological treatment was determined by the blood pressure level
during the first appointment. If the blood pressure measure was greater than or equal
to 140/90 mmHg, the initiation of pharmacological treatment was indicated. If the
blood pressure level was less than 140/90mmHg, the pharmacological treatment was
indicated only if diabetes mellitus, cardiovascular disease, or renal disease were
present as comorbidities (Organización Panamericana de la Salud, 2009). The PAHO
Guidelines explicitly list diabetes mellitus and renal disease as independent
cardiovascular disease risk factors.
Pharmacological treatment adherence with antihypertensive protocols by
physicians was assessed at the treatment appointment in the following manner:
patients were classified as “Yes” (appropriately treated) or “No” (inappropriately
treated) according to the prescribed antihypertensive medication, and listed
comorbidities (Appendix B). For example, if a patient with hypertension and no
associated comorbidities was treated with a β - blocker, angiotensin-converting
enzyme inhibitor (ACEI), angiotensin-receptor blocker (ARB) or calcium-channel
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blocker (CCB), either alone or in combination (up to 2 agents) then he/she was
classified as treated appropriately. If this treatment was not prescribed, then he/she
was classified as inappropriately treated.
Finally, if a patient received both lifestyle modifications recommendations
and received pharmacological treatment following antihypertensive protocols, the
variable “treatment adherence to antihypertensive protocols” was classified as “Yes”
(Table 3.1). If either of the two variables were classified as “No”, the variable
“treatment adherence to antihypertensive protocols” was classified as “No”.	
  
Table 3.1
Assessment of Treatment Compliance with Antihypertensive
Protocols
Lifestyle
Pharmacological
Treatment
Modifications
Treatment
Adherence
Yes
Yes
Yes
Yes
No
No
No
Yes
No
No
No
No
Note. The variable Treatment Adherence is a combination of the
variables Lifestyle Modifications and Pharmacological Treatment.

Assessment of Blood Pressure Control Status
The follow-up appointment was used to assess if the patient reached their
blood pressure goal, as specified in Table 3.2. To fully consider the impact of
comorbidities, the goal blood pressure level recommendations from the PAHO
Guidelines and from the JNC 7 Report were used. Finally, for the remaining patient
categories, a blood pressure goal level of <140/90 mmHg was used, based on a
previous study in Panama in which the prevalence of uncontrolled hypertension was
estimated (McDonald et al., 2012).
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Data Collection Procedures
Once the 383 participants were identified, the clinical record identification
number (CRIN) was collected and a study identification number (Study_ID) was
assigned to each clinical chart. The study identification number went from 001 to
383. This code was stored in electronic format, encrypted using the encryption
software Mac OS X version 10.8.3, and password-protected on the principal
investigator’s personal computer. Only the principal investigator has access to this
file and to the personal computer where it is stored. No other identifier was
collected, such as name, personal identification number, social security number
and/or participant's home address.
Table 3.2
Pressure Level Goals According to Treatment Category
Category

Blood Pressure Goals

Basis

<140/90

JNC 7 Reporta
PAHO Guidelinesb
JNC 7 Reporta
Gorgas Studyc
PAHO Guidelinesb
PAHO Guidelinesb
PAHO Guidelinesb
JNC 7 Reporta
JNC 7 Reporta
Gorgas Studyc
Gorgas Studyc
Gorgas Studyc
Gorgas Studyc

a

HT alone, Stage 1 or 2
HT + Late adulthood (>55 years
old)b
HT + African American
HT + DM
HT + Chronic Kidney Disease
HT + DM + Nephropathy
HT + Coronary Heart Disease
HT + Heart Failure
HT + LVH
HT + Obesity
HT + Dyslipidemia
HT + Asthma

<140/90
<140/90
<130/80
<130/80
<130/80
<140/90
<140/90
<140/90
<140/90
<140/90
<140/90

Note. HT = Hypertension; DM = diabetes mellitus; LVH = left ventricular hypertrophy; JNC =
Joint National Committee; PAHO = Pan American Health Organization. aAs defined in “The
seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and
Treatment of High Blood Pressure: The JNC Report,” by A. V. Chobanian et al., 2003, The
Journal of the American Medical Association, 289(19), 2560-2572. bAs defined in ¨Guías para la
atención integral de las personas con hipertensión arterial [Comprehensive guidelines for the
treatment of hypertensive patients],¨ by Organización Panamericana de la Salud [Pan American
Health Organization], 2009. Republic of Panama. cAs defined in “Prevalencia de factores de
riesgo asociados a Enfermedad Cardiovascular [Prevalence of cardiovascular disease risk
factors],” by Mc Donald et al., 2012. Republic of Panama.
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An electronic data entry form was developed in Microsoft® 2012 Excel Software
to capture the study variables (Appendix A) directly from the clinical chart, without any
paper-based abstraction materials. The data collection was conducted by the principal
investigator. Within the clinical chart, the demographic variables were abstracted from
the “Demographic Information Section” and the clinical variables from the “Medical
Information and Follow-up Section.” Then, when all data were collected, they were
imported to Statistical Analysis System Software (SAS) Version 9.2 and to IBM SPSS
Statistics Software for the analysis.
In order to test reliability and assure the quality of the data, re-abstraction of
approximately 20% of the sample was performed. The following variables were
abstracted: date of birth, age, systolic and diastolic blood pressures during the first and
second appointments, lifestyle modification recommendations during first appointment,
medications prescribed in the first appointment and existing comorbidities.
Race/ethnicity was not referenced in the clinical chart and therefore, could not be
abstracted. A research assistant did the re-abstraction and these data were compared with
the data collected by the principal investigator using the same clinical charts. To assess
the level of agreement between the two abstractors, a kappa statistic was used for
categorical variables and the intraclass correlation coefficient for continuous variables.
The kappa coefficient ranged from 0.854 to 1.000 and the intraclass correlation
coefficient ranged from 0.940 to 0.996, showing very good to excellent agreement
between abstractors (Byrt, 1996).
When all data analysis is completed, all files generated will be moved to an
external storage drive (flash drive) and deleted from the principal investigator’s
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personal computer. The external storage disk will be stored and locked in the
facilities of the University of South Florida at the City of Knowledge in Panama,
where it will remain for five years. After five years, the disk will be destroyed using
the services of a certified company. The principal investigator will attend the disc
destruction and receive a certificate that guarantees that the full process was
executed.

Statistical Analysis
In the univariate analysis, for continuous variables Q-Q plots were used to assess
if the variable was normally distributed. For those variables which were normally
distributed, the mean and standard deviation were used as descriptive statistics; and for
those that were not normally distributed the median and interquartile range (IQR) were
used. For categorical variables, the results were presented as frequencies and
proportions.
A bivariate analysis was performed to compare demographic and clinical
variables with the dependent variable “Blood Pressure Control Status (Uncontrolled,
Controlled)”. An independent sample t test was used for continuous normally distributed
variables, Wilcoxon Sum-Rank test for continuous non-normally distributed variables,
and Fisher’s exact test or chi-squared test for categorical variables, depending if the
observed frequencies in any cell was less than five or not. To assess if the change in the
blood pressure between both treatment and follow-up appointment was significant, a pair
t test was performed. For all comparisons an alpha of 0.05 was used as level of statistical
significance.

	
  

15

Finally, to investigate the relationship between the physician’s adherence to
antihypertensive protocols and the presence of uncontrolled hypertension among
participants, controlling for other covariates, a multivariate analysis was performed using
a logistic regression model.
Covariates were included in the model, in the following order; first, those
variables that had a statistical significant relationship with the dependent variable in the
bivariate analysis: age, number of comorbidities, and the presence of diabetes mellitus.
Second, the variables gender and type of attending physician were forced to be in the
model, based in the association showed in previous studies (CDC, 2012a; Egan, Zhao,
Axon, Brzezinski, & Ferdinand, 2011; Basu & Millett, 2013; Kim et al., 2007; Amar et
al., 2003). Third, those variables considered to be potential confounding variables were
included in the model; being those that provoked a change in the measure of association
(odds ratio, OR) between the dependent and independent variable in more than 10%
(ΔOR>10%).
To determine the presence of effect modification, interactions were tested
between the main effect variable and the covariates included in the model. If an
interaction was observed, stratified models based on the levels of the potential modifier
would be developed, to unveil the association by each stratum.
Finally, to test whether or not our final model provides a good fit to the data, a
Goodness-of-Fit Test was performed.
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CHAPTER FOUR: RESULTS

Univariate Analysis – Patients Characteristics
Demographic Variables. Table 4.1 shows the study sample baseline
characteristics. The participant’s mean age was 56.7 years (±13.6). From the total of
participants, 58.1% (n=68) were females and 41.9% (n=49) were males.
Clinical Variables. For body mass index (BMI), 40.6% (n=41) were obese,
30.7% (n=31) were overweight, 26.7% (n=27) were at healthy weight, and 2.0% (n=2)
were underweight. There were 16 observations with missing values to calculate the BMI.
For hypertension classification, 53.0% (n=62) of participants were at Stage 2, 43.6%
(n=51) were at Stage 1 and 3.4% (n=4) were Prehypertensive. During the first
appointment, the mean systolic blood pressure (SBP) was 150.0 mmHg (±14.7), while the
mean diastolic blood pressure (DBP) was 92.3 mmHg (±9.4). In the second appointment,
the mean SBP was 135.6 mmHg (±18.6) and the mean DBP was 84.7 mmHg (±10.7).
Systolic and diastolic blood pressure significantly decreased between the treatment and
follow-up appointments (14.44 mmHg ±19.3 and 7.60 mmHg ±12.51, respectively;
p<0.0001 for both). For the number of comorbidities, 17.1% (n=20) had zero
comorbidities, 47.0% (n=55) had one comorbidity, 27.4% (n=32) had two comorbidities,
7.7% (n=9) had three and 0.8% (n=1) had one comorbidity. In this study sample, 28.2%
(n=33) had diabetes mellitus, while 71.8% did not. General practitioners attended 62.4%
(n=73) of participants, while 37.6% (n=44) were attended by a specialized medical
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Table 4.1
Baseline Characteristics of Study Population
Characteristic
Age, years; Mean (±SD)
Gender; n (%)
Female
Male
Body Mass Index; n (%)
Underweight (<18.5 kg/m2)
Healthy Weight (18.5 - <25.0 kg/m2)
Overweight (25.0 – 30.0 kg/m2)
Obese (≥30.0 kg/m2)
Hypertension Classification, JNC 7 Stagea; n (%)
Pre Hypertension
Stage 1
Stage 2

56.7 (±13.6)
68 (58.1)
49 (41.9)
2 (2.0)
27 (26.7)
31 (30.7)
41 (40.6)
4 (3.4)
51 (43.6)
62 (53.0)

Treatment App SBP, mmHg; Mean (SD)

150.0 (±14.7)

Treatment App DBP, mmHg; Mean (SD)

92.3 (±9.4)

Follow-up App SBP, mmHg; Mean (SD)

135.6 (±18.6)

Follow-up App DBP, mmHg; Mean (SD)

84.7 (±10.7)

SBP Mean Change, mmHg; Change (SD)*

14.4 (±19.3)

DBP Mean Change, mmHg; Change (SD)*

7.6 (±12.5)

Number of Comorbidities; n (%)
0
1
2
3
4
Diabetes Mellitus among comorbidities; n (%)
Yes
No
Attending physician; n (%)
General Practitioner
Specialist
Blood Pressure Status; n (%)
Uncontrolled
Controlled

20 (17.1)
55 (47.0)
32 (27.4)
9 (7.7)
1 (0.8)
33 (28.2)
84 (71.8)
73 (62.4)
44 (37.6)
78 (66.7)
39 (33.3)

Note. SD = standard deviation; n = number of subjects; JNC = Joint National
Committee; App, appointment; SBP, systolic blood pressure; DBP, diastolic blood
pressure. For continuous and normally distributed variables the mean was used as
central tendency measure. *A pair t-test was used to assess the change in systolic and
diastolic blood pressure change; in both cases p<0.0001.aAs defined in “The seventh
report of the Joint National Committee on Prevention, Detection, Evaluation, and
Treatment of High Blood Pressure: The JNC Report,” by A. V. Chobanian et al, 2003,
The Journal of the American Medical Association, 289(19), 2560-2572.
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doctor. The majority, 66.7% (n=78), had uncontrolled high blood pressure, while 33.3%
(n=39) had their blood pressure below goal levels.
Table 4.2 presents the treatment characteristics of the participants. Regarding the
number of antihypertensive medication, 76.1% (n=89) of cases were prescribed with one
medication, 23.1% (n=27) of cases were prescribed two antihypertensive medications and
0.8% (n=1) was prescribed with three medications. Lifestyle modification
recommendations were given to 43.6% (n=51) of participants, while they weren’t given
to 56.4% (n=66). The majority of physicians adhered to the pharmacological
antihypertensive treatment protocols (98.3%; n=115), while in just 1.7% (n=2) the
protocols were not followed. Combining the lifestyle modification recommendations and
pharmacological antihypertensive treatment to assess compliance with the
antihypertensive protocols, 43.6% (n=51) of participants received treatment following the
PAHO Guidelines, while 56.4% (n=66) did not. The median of treatment days was 31
(IQR=10.50-69.50) in the study sample.
Table 4.2
Treatment Characteristics of Study Population
Characteristic
Number of Antihypertensive medication(s) prescribed; n (%)
1
2
3
Treatment days; Median (IQR)
Lifestyle Modifications recommended; n (%)
Yes
No
Antihypertensive medication(s) following protocols; n (%)
Yes
No
Treatment compliance with antihypertensive protocols; n (%)
Yes
No

89 (76.1)
27 (23.1)
1 (0.8)
31 (10.5-69.5)
51 (43.6)
66 (56.4)
115 (98.3)
2 (1.7)
51 (43.6)
66 (56.4)

Note. n = number of subjects; IQR, interquartile range. For continuous and nonnormally distributed variables the median was used as central tendency measure.
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Bivariate Analysis
Demographic Variables. Table 4.3 presents the results of the bivariate analyses
between the demographic and clinical characteristics, and blood pressure control status.
Those with uncontrolled hypertension were older (58.6 years, ±14.2) than those with
uncontrolled hypertension (53.1 years, ±11.7; p<0.0396). Among those with uncontrolled
hypertension 53.9% were females, compared to those who were controlled (66.7%).
However, this difference was not statistically significant (p=0.1852).
There was a higher proportion of overweight participants in the uncontrolled
group (34.8%) compared to the controlled group (22.8%). However, a higher proportion
of the controlled group (48.6%) than the uncontrolled group (36.4%) were classified as
obese. Nevertheless, the difference between groups was not statistically significant
(p=0.3845).
Clinical Variables. In the uncontrolled group a higher proportion of participants
were at stage 2 hypertension (56.4%) than in the controlled group (46.2%). However, it
was the opposite for stage 1 hypertension, which was less prevalent in the uncontrolled
group (41.0%) than in the controlled group (48.7%). But, the differences found between
these groups were not significant ((p=0.5202).
During the first appointment, the mean systolic blood pressure for the
uncontrolled group was 151.2 mmHg (±15.7) and for the controlled group was 147.7
mmHg (±12.3), with no statistical relationship with the dependent variable (p=0.2234).
At the same appointment, the mean diastolic blood pressure for the uncontrolled group
was 92.4 mmHg (±9.7) and for the controlled group was 92.1 mmHg (±8.8), with no
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Table 4.3
Patients Characteristics by Blood Pressure Control Status
Characteristic
Uncontrolled
Blood Pressure Status; n (%)
Age, years; Mean (SD)
Gender; n (%)
Malea
Female
Body Mass Indexb; n (%)
Healthy Weighta (<25.0 kg/m2)
Overweight (25.0 - <30.0 kg/m2)
Obese (≥30.0 kg/m2)
JNC 7 Staged; n (%)
Pre Hypertensiona
Stage 1
Stage 2
Tx App SBP, mmHg; Mean (SD)
Tx App DBP, mmHg; Mean (SD)

Controlled

p-value*

78 (66.7)

39 (33.3)

NA

58.6 (14.2)

53.1 (11.7)

0.0396

36 (46.1)
42 (53.9)

13 (33.3)
26 (66.7)

0.1852

19 (28.8)
23 (34.8)
24 (36.4)

10 (28.6)
8 (22.8)
17 (48.6)

0.3845c

2 (2.6)
32 (41.0)
44 (56.4)
151.2 (15.7)

2 (5.1)
19 (48.7)
18 (46.2)
147.7 (12.3)

0.5202
0.2234

92.4 (9.7)

92.1 (8.8)

0.8685

e

8.5 (±18.4)

26.4 (±16.4)

<.0001

e

3.6 (±10.5)

15.5 (±6.7)

<.0001

8 (20.5)
23 (59.0)
8 (20.5)

0.0488

34 (87.2)
5 (12.8)

0.0089

31 (79.5)
8 (20.5)

0.5400

13 (33.3)
26 (66.7)

0.4998

23 (59.0)
16 (41.0)

0.6925

33 (14.0-90. 0)

0.4250

SBP Change , mmHg; Change (SD)
DBP Change , mmHg; Change (SD)

Number of Comorbidities; n (%)
0a
12 (15.4)
1
32 (41.0)
≥2
34 (43.6)
Diabetes Mellitus among comorbidities; n (%)
Noa
50 (64.1)
Yes
28 (35.9)
First App Antihypertensive medication(s) prescribedf; n (%)
1a
58 (74.4)
≥2
20 (25.6)
Attending physician; n (%)
Specialista
31 (39.7)
General Practitioner
47 (60.3)
Treatment compliance with antihypertensive protocols; n (%)
Noa
43 (55.1)
Yes
35 (44.9)
Treatment days; Median (IQR)

30.5 (10.0-56.3)

Note. n = number of subjects; NA = do not apply; SD = standard deviation; Ref = reference group;
JNC = Joint National Committee; Tx = Treatment;App = appointment; SBP = systolic blood
pressure; DBP = diastolic blood pressure; IQR = interquartile range. P-values were obtained by
using the t-test for continuous variables, the chi-square test for categorical variables and pait t-test
for pair data. *p<.05. aReference group. bThe body mass index categories Healthy Weight (n=27)
and Underweight (n=2) were collapsed in the category Healthy Weight. cMissing data not included
in the analysis (n=16). dAs defined in “The seventh report of the Joint National Committee on
Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC Report,” by A.
V. Chobanian et al, 2003, The Journal of the American Medical Association, 289(19), 2560-2572.
e
Mean change. fThe antihypertensive medication categories “2” (n=27) and “3” (n=1) were
collapsed in category “2”.
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statistical relationship with the dependent variable (p=0.8685). The reductions in systolic
and diastolic blood pressure were significantly higher in the control group than in the
uncontrolled group (in both cases p<0.0001).
A larger percentage of participants in the uncontrolled group (43.6%) had two or
more comorbidities, compared to those in the controlled group (20.5%). The differences
found between groups in the number of comorbidities were statistically significant
(p=0.0488). The categories “two comorbidities”, “three comorbidities” and “four
comorbidities” were merged due to low frequencies (n=9 and n=1, respectively).
Diabetes mellitus, as a comorbidity, was observed more frequently in the
uncontrolled group (35.9%) than in the control group (12.8%, p=0.0089). There was no
difference in the proportions prescribed with two or more antihypertensive medication in
the uncontrolled group (25.6%) compared to those in the controlled group (20.5%,
p=0.5400). The percentage of participants attended by a general practitioner in the
uncontrolled group (60.3%) was not different compared to the controlled group (66.7%,
p=0.4998).
The percentage of medical doctors that followed the recommendations of the
antihypertensive protocols was 44.9% for the uncontrolled group, compared to the
controlled group (41.0%). However, the differences were not significant (p=0.4998).
Finally, the number of antihypertensive treatment days did not differ for the
uncontrolled group (30.5 days, Interquartile range [IQR]: 10.0-56.3), compared to the
controlled group (33.0 days, IQR=14.0-90.0; p=0.4250).
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Multivariate Analysis
`

Table 4.4 presents the crude and adjusted odds ratio estimates for physician

adherence to antihypertensive protocols and the demographic and clinical characteristics
of the subjects. Physician adherence to antihypertensive protocols was not significantly
associated with blood pressure control status in either the crude or adjusted models.
Table 4.4
Crude and Adjusted Odds Ratios for Physician Adherence to Antihypertensive
Protocols and Covariates
Crude Model
Adjusted Model
Variable
OR (95% CI)
OR (95% CI)
Physician Adherence
1.17 (0.54-2.55)
1.31 (0.48-3.564)
Ref = No
Age
1.03 (1.00-1.06)
1.05 (0.99-1.10)
Diabetes Mellitus
3.81 (1.34-10.84)
2.90 (0.58-14.46)
Ref = No
Gender
0.58 (0.26-1.30)
0.649 (0.25-1.70)
Ref = Male
Attending Physician
0.76 (0.34-1.70)
1.89 (0.54-6.62)
Ref = No
Number of Comorbidities
1 vs 0
0.93 (0.34-2.63)
0.76 (0.17-3.50)
Ref = Zero
Number of Comorbidities
2 vs 0
2.83 (0.87-9.23)
1.20 (0.16-8.93)
Ref = Zero
Body mass index
0.74 (0.28-2.00)
1.46 (0.31-6.87)
Obese vs Healthy Weight
Body mass index
Overweight vs Healthy
1.51 (0.50-4.60)
2.03 (0.56-7.37)
Weight
Note. OR = odds ratio; CI = confidence interval; Ref = reference group.

To determine the presence of effect modification, interactions were tested
between the main effect variable (physician adherence to antihypertensive protocols by
medical doctors) and the covariates included in the model. Table 4.5 presents the pvalues for the interaction terms. A significant interaction was found with age (p=0.0454).
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There were no significant differences by levels of the number of comorbidities
(p=0.6539), diabetes mellitus (p=0.7194), gender (p=0.3941), and type of
attending physician (p=0.7286). For body mass index, the interaction was dropped from
Table 4.5
Interaction Terms with Variables Included in the Model
Variable
p-value*
Age
Diabetes Mellitus
Gender
Attending Physician
Number of Comorbidities
Body mass index
*p<.05.

0.0454
0.7194
0.3941
0.7286
0.7883
0.0311

the final model, because the point estimate was not estimable for the main effect variable
due to low numbers in the healthy weight category.
Stratified models were run for the potential effect modifier “age”, using a cut
point at the mean age (56.7 years); one model for those below or equal to the mean, and
Table 4.6
Stratified Models by Age as a Potential Modifier
Age ≤ 56.7 years
OR (95% CI)
Physician Adherence
0.85 (0.22-3.22)
Ref = No
Gender
0.85 (0.29-2.51)
Ref = Male
Attending Physician
0.73 (0.18-2.97)
Ref = No
Age > 56.7 years
OR (95% CI)
Physician Adherence
1.61 (0.35-7.34)
Ref = No
Gender
0.19 (0.03-1.04)
Ref = Male
Attending Physician
1.31 (0.28-6.10)
Ref = No
Note. OR = odds ratio; CI = confidence interval; Ref = reference
group.
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one model for those above the mean. Inestimable parameters were found for the variables
number of comorbidities, the presence of diabetes mellitus and BMI; therefore, these
variables were dropped from the models; and the models were run again.
In Table 4.6 are shown the results for the models stratified by age. From these
models it can be observed that the estimates were different for the levels of age. These
findings suggest that age is a potential effect modifier for the association between
uncontrolled hypertension and the physician’s adherence to antihypertensive protocols.
The Hosmer-Lemeshow Goodness-of-Fit test indicated a good model fit
(p=0.5717).
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CHAPTER FIVE: DISCUSSION

Key Findings
The aim of this study was to describe the characteristics of uncontrolled
hypertension in a primary healthcare center and the factors associated with this condition.
This study was designed as a feasibility study to assess the current treatment
practices for hypertensive adults. One of the critical findings of this study is that 66.7%
of the study sample had uncontrolled hypertension, a result that differs from another
study in Panama in which the prevalence of uncontrolled hypertension was 47.2%
(McDonald et al., 2012). However, this results was not unexpected considering that our
study was clinically based at a primary healthcare center serving a single county of the
Panama province, the target population was the hypertensive adult population visiting the
clinic, and, finally, the study used a more conservative blood pressure cut point to define
uncontrolled hypertension (>130/80 mmHg, or >140/90 mmHg, depending on the type of
comorbidities). The Gorgas study was population based, with a target population of the
general adult population (hypertensive and non-hypertensive adults) in the two main
Panama provinces (in which the 57.4% of the total Panamanian population reside), and
defined uncontrolled hypertension using a more liberal cut point (>140/90 mmHg for all
hypertensive population, regardless the type of comorbidities).
A logistic regression model was used to investigate the relationship between
physician adherence to antihypertensive protocols and the presence of uncontrolled
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hypertension. A significant interaction term was found between physician adherence to
protocols and age. In the stratified models, the odds ratios for physician adherence to
protocols were in opposite directions, although the estimates were not significantly
different from one. These results suggest that age could be a potential effect modifier for
the association between physician adherence to antihypertensive protocols and the
presence of uncontrolled hypertension. However, due to the small sample size, the
possible role of age as an effect modifier for the mentioned the relationship needs further
examination.
There is a potential biologic explanation for these findings. A study derived from
the Framingham cohort, showed that systolic blood pressure increased linearly with age
during lifetime; however, diastolic blood pressure increased linearly until the age of 50 to
60 years, and after this tended to level off over a decade, and later on may stay the same
or decrease (Franklin et al., 1997). This phenomenon produces a steep increase, after 50
to 60 years, in pulse pressure (systolic minus diastolic blood pressure); and became,
along with systolic blood pressure, potent cardiovascular risk factors in this age group
(Chobanian et al., 2003; Mancia et al., 2007). However, for those aged <50 years,
diastolic blood pressure is more important cardiovascular risk factor than systolic blood
pressure or pulse pressure (Franklin et al, 2001; Chobanian et al., 2003). The joint
increase of systolic and diastolic blood pressure until the age of 50 years, makes the
pharmacological titration process easier for physicians since both systolic and diastolic
blood pressure will be relatively high; however for those above 50 years old, isolated
systolic hypertension is more expected, and therefore it will be difficult to induce a
decrease in systolic blood pressure without a decrease in diastolic blood pressure, that
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could lead to hypotension symptoms; which makes hypertension control in this age group
more difficult. This is supported by several studies in primary care settings that
demonstrated that 75% of physicians failed to initiate hypertension treatment in older
individuals with systolic blood pressure 140 – 159 mmHg and most of them did not chase
control rates (systolic blood pressure <140 mmHg; Hyman, Pavlik, & Vallbona, 2000;
Berlowitz et al., 1998).
In the bivariate analyses the following variables were associated with having
uncontrolled hypertension: age, number of comorbidities and the presence of diabetes
mellitus. However, in the adjusted models these variables were no longer significant.
Other studies have reported an association between increasing age and
uncontrolled hypertension (CDC, 2012a; Mejía-Rodríguez et al., 2009); while a recent
study by Basu and Millett (2013) reported that age was not associated with uncontrolled
hypertension in middle-income countries. However, the statistically significant
interaction found in our study (between age and the physician adherence to
antihypertensive protocols), was not considered in these studies.
The association found between the number of comorbidities and having
uncontrolled hypertension is consistent with a previous study that demonstrated similar
findings (Amar et al, 2003); however, in the previously mentioned study, the risk factors
considered as comorbidities were not exactly the same than the comorbidities defined in
the current study. We used the Panamanian Guidelines for the Hypertensive Population
Treatment (Organización Panamericana de la Salud, 2009) to define these comorbidities,
so the role of specific comorbidities in the development of uncontrolled hypertension is a
topic that will prompt more research.
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For diabetes mellitus, we found that 28.2% of study sample had this condition as a
comorbidity, in contrast with the 55% reported by a previous study in Panama
(McDonald, 2012). Diabetes mellitus, as a comorbidity, was associated with having
uncontrolled hypertension; this finding is consistent with the literature that has
demonstrated a similar relationship (Amar et al, 2003; Egan et al., 2011; MejíaRodríguez et al., 2009).
In the bivariate analysis, no associations were found for gender, body mass index,
hypertension stage (according to the classification of the JNC 7 Report; Chobanian et al,
2003), systolic and diastolic blood pressure during the treatment appointment, number of
antihypertensive medications prescribed, type of attending physician, time since
treatment started, and treatment following protocols recommendations. However, several
studies had shown the relationship between these independent variables and having
uncontrolled hypertension (Egan et al, 2011; CDC, 2012a; Basu & Millett, 2013; MejíaRodríguez, 2009; Kim et al, 2009; Mounier-Vehier, Sanchez-Ponton, Delsart, &
Miljkovic, 2010; Hyman & Pavlik, 2002). These results could be a reflection of one of
the main limitations of this study, the sample size.

Limitations and Strengths
This study was designed as a feasibility study and it provides some insight on how
future studies need to be designed; however some important limitations should be
mentioned.
The main limitation is the sample size, which was a third of the required number
(117 out of 383 participants), resulting in a lack of power to detect statistically significant
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differences. This means that even when there was a difference between those patients that
were treated following the protocols and those that were not, our study was not able to
detect a statistically significant difference between these groups.
These results may not be generalizable to the general population because the
study center was not chosen by randomization; instead it was selected based on
accessibility and available permission to perform the study. As the study was based on
clinical chart review, the diagnosis of hypertension was not independently confirmed.
Also, data were not collected for some important covariates that have previously
been shown to have an association with uncontrolled hypertension, such as smoking
history (Amar et al., 2003; Chmiel et al., 2012), cholesterol levels (Amar et al., 2003),
renal function (Mounier-Vehier et al., 2010), therapeutic inertia (Egan et al., 2011),
income (CDC, 2012a; Basu & Millett, 2013), education (Mounier-Vehier et al., 2010)
and alcohol intake (Mounier-Vehier et al., 2010). Race/ethnicity was not recorded in the
clinical chart, and therefore could not be considered in the analysis. Approximately 14%
of observations were missing height, weight or both to calculate body mass index, and
were not included in the multivariate analysis. Another limitation was that patient
compliance with antihypertensive treatment and lifestyle modifications recommendations
were not assessed. From the mentioned above and the fact that our design does not let us
to establish temporality, no statements on causality or prevalence of uncontrolled
hypertension in the general population can be derived.
The strengths of this study include that it was designed to minimize sources of
systematic error. Multivariate logistic regression models were developed to test
association between physician adherence to protocols and uncontrolled hypertension.
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Another strength of this study is that a more conservative blood pressure cut point
(>130/80 mmHg) was used for those with diabetes mellitus or any kind of nephropathy to
establish the presence of uncontrolled hypertension. Other studies have used a set blood
pressure cut point of >140/90 mmHg for all subjects.

Conclusions
Uncontrolled hypertension is a public health problem worldwide, and the
population prevalence estimates for Panama is 47.2%. Among this study population the
prevalence of uncontrolled hypertension was 66.7%, which is reflective of a clinic-based
population but it cannot be generalized to the general population.
Nearly half of the attending physicians did not follow the recommendations given
by current antihypertensive protocols, primarily due to a lack of recommending lifestyle
modifications. Physician adherence to pharmacological treatment recommendations was
high (98.3%). However, it was not possible to demonstrate an association between
physician adherence to antihypertensive protocols and the presence of uncontrolled
hypertension, in the multivariate analysis.
Further research is necessary to fully assess the association between age, number
of comorbidities and presence of diabetes mellitus with uncontrolled hypertension;
specifically to assess the role of age as a potential modifier for the association between
uncontrolled hypertension and the physician adherence to antihypertensive protocols
recommendations. Is imperative to know which antihypertensive protocols
recommendations work for what specific age groups, because specific recommendations
can be restated to benefit the hypertensive population with poor blood pressure control.

	
  

31

As a feasibility study, this research provides valuable insight in the design and
direction of future studies. For example, future studies should comprehensively examine
the role of age in uncontrolled hypertension and as a potential effect modifier of
physician adherence to protocols. In addition, future studies should adequately control for
all potential confounders, should be appropriately sized, and should include a measure of
patient compliance to antihypertensive protocols.

Recommendations
Further research needs to be conducted using an adequate sample size to confirm
the results of this study. In addition, further exploration of the roles of age in uncontrolled
hypertension is warranted.
In Panama, further research in hypertension is necessary to determine the
population prevalence of uncontrolled hypertension using a blood pressure cut point
specific for individual comorbidities; as well as, to establish the risk factors associated
with uncontrolled hypertension.
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Appendix A: Electronic Data Entry Form
	
  
Study Identification Number:
	
  
Age:

Gender:

Height:

Weight:

☐ Male
☐ Female

Race/Ethnicity

☐ Indigenous
☐ African American
☐ Other:

	
  
	
  
Comorbidities:
1
2.
3.

4.
5.
6.

	
  
Treatment Appointment
Blood Pressure:

Date:

Lifestyle Modifications?

Yes
No

Antihypertensive
1.
2.
	
  
Follow-Up Appointment

Dosage

Blood Pressure:
Antihypertensive
1.
2.

Date:
Dosage

	
  

	
  

Frequency
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Frequency

Appendix A: (Continued)
	
  

According to the antihypertensive medication given in the first appointment and
according to the treatment category, was the patient treated according to protocols?
☐ Yes
☐ No
According to the blood pressure in the second appointment, was the expected
blood pressure level reached?
☐ Yes
☐ No
Type of Attending Physician
☐ General Practitioner

☐ Specialist
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Appendix B: Classification in Appropriately and Inappropriately Treated
Hypertension According to the Guidelines of the Pan American Health
Organization – Republic of Panama
Table B.1
Treatment Classification According to the Guidelines of the Pan American
Health Organizationa
Category
HT alone, Stage 1 or 2b
HT + Late adulthood
(>55 years old)
HT + African American
HT + Diabetes Mellitus (DM)
HT + Chronic Kidney Disease
HT + DM + Nephropathy
HT + Coronary Heart Disease
HT + Heart Failure
HT + Left Ventricular Hypertrophy
HT + Obesity
HT + Dyslipidemia
HT + Asthma

Appropriately Treated
Treated with a diuretic, β-blocker, ACEI, ARB
or CCB either alone or in combination (up to 2
agents)
Treated with a diuretic, β-blocker, ACEI, ARB,
α-blockers, either alone or in combination
Treated with a diuretic, ACEI, CCB, ARB, αblockers, either alone or in combination
Treated with a ACEI, ARB, diuretic, CCB, αblocker, β-blocker either alone or in combination
Treated with a loop diuretic alone or in
combination with CCB, ACEI or ARB
Treated with either a ACEI or a ARB alone or in
combination with CCB’s, diuretics, α-blockers
or β-blockers
Treated with a β-blocker, ACEI, ARB, CCB
either alone or in combination
Treated with a ACEI, ARB, β-blocker, diuretics,
Aldosterone Antagonist, either alone or in
combination
Treated with ACEI, ARB, diuretics, β-blocker,
or CCB, either alone or in combination
Treated with a ACEI, ARB, diuretics, β-blocker,
or CCB, either alone or in combination
Treated with a ACEI, ARB, CCB, thiazide
diuretic, or β-blocker, either alone or in
combination
Treated with any antihypertensive medication,
either alone or in combination, excluding any βblocker (is totally contraindicated)

Note. DM = diabetes mellitus; ACEI = angiotensin-converting enzyme inhibitor; ARB =
angiotensin-II-receptor blocker; CCB = calcium channel blocker. aAdapted from “Estimated
annual direct expenditures in the United States as a result of inappropriate hypertension treatment
according to national guidelines,” by S. Balu, 2009, Clinical Therapeutics, 31(7), p. 1581-1595.
b
As defined in “The seventh report of the Joint National Committee on Prevention, Detection,
Evaluation, and Treatment of High Blood Pressure: The JNC Report,” by A. V. Chobanian et al,
2003, The Journal of the American Medical Association, 289(19), 2560-2572.
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Appendix C: University of South Florida’s Institutional Review Board Letter of
Approval
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Appendix C: (Continued)
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Appendix D: University of South Florida’s Institutional Review Board Letter of
Approval of Amendment 1
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Appendix E: Panama’s Institutional Review Board Letter of Approval (Spanish)
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Appendix F: Panama’s Institutional Review Board Letter of Approval (Translation)
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